Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
2 findings from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) probably leads to higher mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).
2 findings from 1 review
Leaving the study early · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review